Published in Cancer Weekly, November 11th, 2003
The recently received capital represents the initial tranche of a multi-year, $20 million investment commitment.
Biovest, which is designated the National Cell Culture Center by the National Institutes of Health, is utilizing a portion of this investment to expand its core businesses of contract biologic production and the manufacture and sale of proprietary cell culture production equipment.
Additionally, a portion of the invested capital...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.